Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study, JAMA Pediatr, vol.169, pp.230-238, 2015.,
URL : https://hal.archives-ouvertes.fr/hal-01258705
Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study, Lancet, vol.371, pp.813-833, 2008. ,
Decreasing prevalence in cerebral palsy: a multi-site European populationbased study, Dev Med Child Neurol, vol.58, pp.85-92, 1980.,
URL : https://hal.archives-ouvertes.fr/hal-02007920
The panorama of cerebral palsy in Sweden. XI. Changing patterns in the birth-year period 2003-2006, Acta Paediatr, vol.103, pp.618-642, 2014. ,
Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus, Cochrane Database Syst Rev, issue.1, p.4661, 2009. ,
Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies, Dev Med Child Neurol, vol.37, pp.473-84, 1995. ,
Treatment with magnesium sulphate in pre-term birth: a systematic review and metaanalysis of observational studies, J Obstet Gynaecol, vol.32, pp.135-175, 2012. ,
Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants, Am J Obstet Gynecol, vol.186, pp.1111-1119, 2002. ,
Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial, Lancet, vol.359, pp.1877-90, 2002. ,
Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial, JAMA, vol.290, pp.2669-76, 2003. ,
A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy, N Engl J Med, vol.359, pp.895-905, 2008. ,
Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial, BJOG, vol.114, pp.310-318, 2007. ,
Benefit of magnesium sulfate given before very preterm birth to protect infant brain, Pediatrics, vol.121, pp.225-231, 2008. ,
Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus, Cochrane Database Syst Rev, issue.3, p.4661, 2007. ,
Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis, Obstet Gynecol, vol.114, pp.354-64, 2009. ,
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis, Am J Obstet Gynecol, vol.200, pp.595-609, 2009. ,
Effects and Safety of Magnesium Sulfate on Neuroprotection: A Meta-analysis Based on PRISMA Guidelines, Medicine, vol.95, p.2451, 2016. ,
, American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection, Obstet Gynecol, vol.115, pp.669-71, 2010.
, American College of Obstetricians and Gynecologists, Society for MaternalFetal Medicine. ACOG Obstetric Care Consensus No. 3: Periviable Birth, Obstet Gynecol, vol.126, pp.82-94, 2015.
, Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines, 2010.
SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection, J Obstet Gynaecol Can, vol.33, pp.516-545, 2011. ,
, National Collaborating Centre for Women's and Children's Health (UK)
, Preterm Labour and Birth, 2015.
Prevention of preterm birth in women at risk: selected topics, 2014. ,
, Antenatal magnesium sulphate for fetal neuroprotection, 2013.
, Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE), Syst Rev, vol.1, p.21, 2012.
Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)-study protocol, BMC Pregnancy Childbirth, vol.13, p.91, 2013. ,
Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit, Aust N Z J Obstet Gynaecol, vol.52, pp.356-60, 2012. ,
Evaluation of the clinical use of magnesium sulfate for cerebral palsy prevention, Obstet Gynecol, vol.121, pp.235-275, 2013. ,
A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation, Aust N Z J Obstet Gynaecol, vol.55, pp.90-93, 2015. ,
Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants, Sci Rep, vol.5, p.14732, 2015. ,
, magnesium sulfate before anticipated preterm birth for neuroprotection, Patient safety checklist, vol.120, issue.7, pp.432-435, 2012.